Pharmacogenomics examines how genetic differences shape an individual’s response to anti-obesity medications. Variations in genes that govern drug metabolism, receptor signaling, and energy regulation can impact both the effectiveness and safety of obesity treatments. By analyzing a person’s pharmacogenomic profile, clinicians can personalize obesity therapy—choosing the right medication, fine-tuning dosages, and reducing the risk of adverse effects. This individualized approach targets specific metabolic pathways and genetic predispositions, which can lead to improved treatment outcomes. Progress in pharmacogenomics is driving precision medicine in obesity management, allowing for therapeutic strategies that are tailored to the patient. The result: more effective weight loss, better metabolic health, and overall enhanced patient care.
Connect, collaborate, and contribute to driving excellence in obesity research, clinical practice, and public health approaches globally.
